GHTF (Global Harmonization Task Force) adverse events group reports on progress:
This article was originally published in Clinica
Study Group 2 of the Global Harmonization Task Force (GHTF), whose remit covers harmonising adverse events, vigilance data collection and reporting systems, has posted a summary of its June 1-3 meeting in Milwaukee, Wisconsin on its website. The meeting analysed and summarised progress on the study group's documents. Among other developments, the group approved a new work item on the electronic format for adverse event reporting (SG2 N72R4) and the nomination of Jorge Garcia of the Australian Therapeutics Goods Administration as the new chairman of SG2, as of September. The next meeting will be held in Gaithersburg, Maryland, on September 12-16.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.